Form 4: Regulus Therapeutics Executive Sells Shares to Cover Tax Obligations

Preston Klassen, President & Head of R&D at Regulus Therapeutics, sold 31,445 shares of common stock on January 13, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Summary

• Preston Klassen, President & Head of R&D at Regulus Therapeutics Inc., sold 31,445 shares of common stock on January 13, 2025.
• The sale was executed at a price of $1.2632 per share.
• The transaction was conducted to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The vesting of these RSUs commenced on January 9, 2025.
• The sale was made pursuant to a pre-existing 10b5-1 plan, indicating that the Reporting Person had irrevocably elected to satisfy tax obligations through this sale.
• Following the transaction, Klassen directly owns 36,055 shares of Regulus Therapeutics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale of shares to cover tax obligations, which is a common practice. It doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The sale was conducted under a pre-existing 10b5-1 plan, suggesting it was planned and not based on current market conditions or inside information.

Future Outlook

There is no future outlook information provided in this document.

Industry Context

This is a routine transaction related to executive compensation and tax obligations. It is common for executives to sell shares to cover taxes when RSUs vest. The use of a 10b5-1 plan indicates that the sales were pre-planned.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen often see similar transactions from their executives.
• The use of 10b5-1 plans is a standard method to avoid accusations of insider trading, aligning with best practices in corporate governance.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price, but it is unlikely to be significant given the reason for the sale and the existence of the 10b5-1 plan.

Key Dates